{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Amin KM"],"funding":["the Deanship of scientific research at Umm Al-Qura University, Saudi Arabia"],"pagination":["1954"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9501832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(9)"],"pubmed_abstract":["Inhibition of PDE5 results in elevation of cGMP leading to vascular relaxation and reduction in the systemic blood pressure. Therefore, PDE5 inhibitors are used as antihypertensive and antianginal agents in addition to their major use as male erectile dysfunction treatments. Previously, we developed a novel series of 34 pyridopyrazinone derivatives as anticancer agents (series <b>A</b>-<b>H</b>). Herein, a multi-step in silico approach was preliminary conducted to evaluate the predicted PDE5 inhibitory activity, followed by an in vitro biological evaluation over the enzymatic level and a detailed SAR study. The designed 2D-QSAR model which was carried out to predict the IC<sub>50</sub> of the tested compounds revealed series <b>B</b>, <b>D</b>, <b>E</b> and <b>G</b> with nanomolar range of"],"journal":["Pharmaceutics"],"pubmed_title":["Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties."],"pmcid":["PMC9501832"],"funding_grant_id":["22UQU4290565DSR72"],"pubmed_authors":["Abdel Rahman DE","Abdellattif MH","Elkamhawy A","Elsaid FG","Ammar UM","El-Badry OM","Abourehab MAS","Amin KM","El-Maghrabey MH","El Hamd MA"],"additional_accession":[]},"is_claimable":false,"name":"Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties.","description":"Inhibition of PDE5 results in elevation of cGMP leading to vascular relaxation and reduction in the systemic blood pressure. Therefore, PDE5 inhibitors are used as antihypertensive and antianginal agents in addition to their major use as male erectile dysfunction treatments. Previously, we developed a novel series of 34 pyridopyrazinone derivatives as anticancer agents (series <b>A</b>-<b>H</b>). Herein, a multi-step in silico approach was preliminary conducted to evaluate the predicted PDE5 inhibitory activity, followed by an in vitro biological evaluation over the enzymatic level and a detailed SAR study. The designed 2D-QSAR model which was carried out to predict the IC<sub>50</sub> of the tested compounds revealed series <b>B</b>, <b>D</b>, <b>E</b> and <b>G</b> with nanomolar range of","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-04-08T11:52:11.642Z","creation":"2025-02-19T00:44:25.484Z"},"accession":"S-EPMC9501832","cross_references":{"pubmed":["36145702"],"doi":["10.3390/pharmaceutics14091954"]}}